Understanding the molecular mechanism responsible for developing therapeutic radiation-induced radioresistance of rectal cancer and improving the clinical outcomes of radiotherapy - A review

References

• Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018. 103:7–15. doi:10.1016/j.ejca.2018.07.129.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Roeder F, Meldolesi E, Gerum S, Valentini V, Rödel C. Recent advances in (chemo-) radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol. 2020;15(1):262. doi:10.1186/s13014-020-01695-0.
   PubMed Web of Science ®Google Scholar
• Abraha I, Aristei C, Palumbo I, Lupattelli, M, Trastulli, S, Cirocchi, R, De Florio, R, Valentini, V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev. 2018;10(10):CD002102. doi:10.1002/14651858.CD002102.pub3
   PubMedGoogle Scholar
• Tam SY, Wu VWC. A review on the special radiotherapy techniques of colorectal cancer. Front Oncol. 2019. 9:208. doi:10.3389/fonc.2019.00208.
   PubMed Web of Science ®Google Scholar
• Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum. 2013;56(1):14–19. doi:10.1097/DCR.0b013e3182741929.
   PubMed Web of Science ®Google Scholar
• Alamilla-Presuel JC, Burgos-Molina AM, González-Vidal A, Sendra-Portero F, Ruiz-Gómez MJ. Factors and molecular mechanisms of radiation resistance in cancer cells. Int J Radiat Biol. 2022;98(8):1301–1315. doi:10.1080/09553002.2022.2047825.
   PubMed Web of Science ®Google Scholar
• Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny A-S, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit. 2021. 27:e934116. doi:10.12659/MSM.934116.
   PubMed Web of Science ®Google Scholar
• Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences. Strahlenther Onkol. 2012;188(7):616–627. doi:10.1007/s00066-012-0085-4.
   PubMed Web of Science ®Google Scholar
• Bayer C, Shi K, Astner ST, Maftei CA, Vaupel P. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys. 2011;80(4):965–968. doi:10.1016/j.ijrobp.2011.02.049.
   PubMed Web of Science ®Google Scholar
• Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. Biomed Res Int. 2015. 2015:549412. doi:10.1155/2015/549412.
   PubMed Web of Science ®Google Scholar
• Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117–1133. doi:10.1177/1947601911423654.
   PubMedGoogle Scholar
• Brown JM, Recht L, Strober S. The promise of targeting macrophages in cancer therapy. Clin Cancer Res. 2017;23(13):3241–3250. doi:10.1158/1078-0432.CCR-16-3122.
   PubMed Web of Science ®Google Scholar
• Cook PJ, Thomas R, Kingsley PJ, Shimizu F, Montrose DC, Marnett LJ, Tabar VS, Dannenberg AJ, Benezra R. Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma. Neuro Oncol. 2016;18(10):1379–1389. doi:10.1093/neuonc/now049.
   PubMed Web of Science ®Google Scholar
• Blagov AV, Markin AM, Bogatyreva AI, Tolstik TV, Sukhorukov VN, Orekhov AN. The role of macrophages in the pathogenesis of atherosclerosis. Cells. 2023;12(4):522. doi:10.3390/cells12040522.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng Z, Liu J, Li, H, Su, Q, Zhang, J, Huang, P, Wang, W, Liu, J. Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance. Bioact Mater. 2022;16:359–371.10.1016/j.bioactmat.2021.12.033
   PubMed Web of Science ®Google Scholar
• Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol. 2020. 22:90–97. doi:10.1016/j.ctro.2020.04.001.
   PubMed Web of Science ®Google Scholar
• De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123(10):2229–2238. doi:10.1002/ijc.23925.
   PubMed Web of Science ®Google Scholar
• Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59. doi:10.1186/s12964-020-0530-4.
   PubMed Web of Science ®Google Scholar
• Huang EY, Chang JC, Chen HH, Hsu CY, Hsu HC, Wu KL. Carcinoembryonic antigen as a marker of radioresistance in colorectal cancer: a potential role of macrophages. BMC Cancer. 2018;18(1):321. doi:10.1186/s12885-018-4254-4.
   PubMedGoogle Scholar
• Liu L, Zhang Z, Zhou L, Hu L, Yin C, Qing D, Huang S, Cai X, Chen Y. Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. Exp Cell Res. 2020;391(2):111956. doi:10.1016/j.yexcr.2020.111956.
   PubMed Web of Science ®Google Scholar
• Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218. doi:10.1038/s41392-021-00641-0.
   PubMed Web of Science ®Google Scholar
• Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, Carbó N, Bragado P. Cancer-associated fibroblasts in breast cancer treatment response and metastasis. Cancers Basel. 2021;13(13):3146. doi:10.3390/cancers13133146.
   PubMed Web of Science ®Google Scholar
• Pathak S, Banerjee A. Emerging importance of microRNA in early detection of colorectal cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(1):2–3. doi:10.2174/187153032101201210095139.
   PubMed Web of Science ®Google Scholar
• Wang R, Wei J, Zhang S, Wu X, Guo J, Liu M, Du K, Xu J, Peng L, Lv Z, et al. Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of hedgehog signaling pathway in colon cancer. Oncotarget. 2016;7(52):86816–86828. doi:10.18632/oncotarget.13559.
   PubMedGoogle Scholar
• Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Disease. 2013;4(10):e875. doi:10.1038/cddis.2013.407.
   PubMedGoogle Scholar
• Tian K, Tao Z, Chen Y, Du J, Chen M, Wang D, Li Z. KCNE4 expression is correlated with the pathological characteristics of colorectal cancer patients and associated with the radioresistance of cancer cells. Pathol Res Pract. 2023. 241:154234. doi:10.1016/j.prp.2022.154234.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Y, Zhang Q, Liu B, Cheng Y, Zhang Y, Sun Y, Liu J. Exosomal miR-590-3p derived from cancer-associated fibroblasts confers radioresistance in colorectal cancer. Mol Ther Nucleic Acids. 2020. 24:113–126. doi:10.1016/j.omtn.2020.11.003.
   PubMedGoogle Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–1609.
   PubMed Web of Science ®Google Scholar
• Kma L, Baruah TJ. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation. Biotechnol Appl Biochem. 2022;69(1):248–264. doi:10.1002/bab.2104.
   PubMed Web of Science ®Google Scholar
• Karami Fath M, Ebrahimi M, Nourbakhsh E, Zia Hazara A, Mirzaei A, Shafieyari S, Salehi A, Hoseinzadeh M, Payandeh Z, Barati G, et al. PI3K/Akt/mTOR signaling pathway in cancer stem cells. Pathol Res Pract. 2022;237:154010. doi:10.1016/j.prp.2022.154010.
   PubMed Web of Science ®Google Scholar
• Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y, Ismail T, Beggs AD. Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers Basel. 2020;12(5):1278. doi:10.3390/cancers12051278.
   PubMed Web of Science ®Google Scholar
• Xiao SY, Yan ZG, Zhu XD, Qiu J, Lu YC, Zeng FR. LncRNA DLGAP1-AS2 promotes the radioresistance of rectal cancer stem cells by upregulating CD151 expression via E2F1. Transl Oncol. 2022. 18:101304. doi:10.1016/j.tranon.2021.101304.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tao L, Yi J, Song H, Chen L. The role of canonical wnt signaling in regulating radioresistance. Cell Physiol Biochem. 2018;48(2):419–432. doi:10.1159/000491774.
   PubMedGoogle Scholar
• Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–1368. doi:10.1038/nm.2890.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Manoharan I, Hong Y, Swafford D, Majumdar T, Taketo MM, Manicassamy B, Koni PA, Thangaraju M, Sun Z, et al. Canonical wnt signaling in dendritic cells regulates Th1/Th17 responses and suppresses autoimmune neuroinflammation. J Immunol. 2015;194(7):3295–3304. doi:10.4049/jimmunol.1402691.
   PubMed Web of Science ®Google Scholar
• Lento W, Ito T, Zhao C, Harris JR, Huang W, Jiang C, Owzar K, Piryani S, Racioppi L, Chao N, et al. Loss of β-catenin triggers oxidative stress and impairs hematopoietic regeneration. Genes Dev. 2014;28(9):995–1004. doi:10.1101/gad.231944.113.
   PubMed Web of Science ®Google Scholar
• Firat E, Niedermann G. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition. Oncotarget. 2016;7(34):54883–54896. doi:10.18632/oncotarget.10702.
   PubMedGoogle Scholar
• Jun S, Jung YS, Suh HN, Wang W, Kim MJ, Oh YS, Lien EM, Shen X, Matsumoto Y, McCrea PD, et al. LIG4 mediates wnt signalling-induced radioresistance. Nat Commun. 2016;7(1):10994. doi:10.1038/ncomms10994.
   PubMedGoogle Scholar
• Zhong X, Zhou B, Lv Z, Liu Y. RNF6 enhances radioresistance in colorectal cancer via activating the wnt pathway. J BUON. 2021;26(5):1925–1930.
   PubMedGoogle Scholar
• Mo JS, Park HW, Guan KL. The hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–656. doi:10.15252/embr.201438638.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Liu Q, Wang Y, Tian C, Yang Q, Zhao Y, Liu L, Wu G, Xu S. CDK5 activates hippo signaling to confer resistance to radiation therapy via upregulating TAZ in lung cancer. Int J Radiat Oncol Biol Phys. 2020;108(3):758–769. doi:10.1016/j.ijrobp.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Ibar C, Irvine KD. Integration of hippo-YAP signaling with metabolism. Dev Cell. 2020;54(2):256–267. doi:10.1016/j.devcel.2020.06.025.
   PubMed Web of Science ®Google Scholar
• Yao PA, Wu Y, Zhao K, Li Y, Cao J, Xing C. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Disease. 2022;13(2):103. doi:10.1038/s41419-022-04554-w.
   PubMed Web of Science ®Google Scholar
• Ouellette MM, Zhou S, Yan Y. Cell signaling pathways that promote radioresistance of cancer cells. Diagno (Basel). 2022;12(3):656. doi:10.3390/diagnostics12030656.
   PubMedGoogle Scholar
• Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442–458. doi:10.2174/156652409788167087.
   PubMed Web of Science ®Google Scholar
• Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585–5594. doi:10.1158/1078-0432.CCR-12-0858.
   PubMed Web of Science ®Google Scholar
• Dengler VL, Galbraith M, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2014;49(1):1–15. doi:10.3109/10409238.2013.838205.
   PubMed Web of Science ®Google Scholar
• Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012;31(11):2448–2460. doi:10.1038/emboj.2012.125.
   PubMed Web of Science ®Google Scholar
• Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 2001;276(11):7919–7926. doi:10.1074/jbc.M010189200.
   PubMed Web of Science ®Google Scholar
• Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004;23(9):1949–1956. doi:10.1038/sj.emboj.7600196.
   PubMed Web of Science ®Google Scholar
• Hubbi ME, Luo W, Baek JH, Semenza GL. MCM proteins are negative regulators of hypoxia-inducible factor 1. Mol Cell. 2011;42(5):700–712. doi:10.1016/j.molcel.2011.03.029.
   PubMed Web of Science ®Google Scholar
• Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt, T, Poulsom, R, Oukrif, D, Alison, MR and Wright, NA. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64(23):8492–8495. doi:10.1158/0008-5472.CAN-04-1708.
   PubMed Web of Science ®Google Scholar
• Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers Basel. 2015;7(4):2443–2458. doi:10.3390/cancers7040902.
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. doi:10.1038/s41573-018-0004-1.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24(8):1277–1289. doi:10.1038/s41591-018-0096-5.
   PubMed Web of Science ®Google Scholar
• Cannan WJ, Tsang BP, Wallace SS, Pederson DS. Nucleosomes suppress the formation of double-strand DNA breaks during attempted base excision repair of clustered oxidative damages. J Biol Chem. 2014;289(29):19881–19893. doi:10.1074/jbc.M114.571588.
   PubMed Web of Science ®Google Scholar
• Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37(8):2539–2548. doi:10.1093/nar/gkp100.
   PubMed Web of Science ®Google Scholar
• Kim W, Lee S, Seo D. Cellular stress responses in radiotherapy. Cells. 2019;8(9):1105. doi:10.3390/cells8091105.
   PubMed Web of Science ®Google Scholar
• Babaye Abdollahi B, Malekzadeh R, Pournaghi Azar F, Salehnia F, Naseri AR, Ghorbani M, Hamishehkar H, Farajollahi AR. Main approaches to enhance radiosensitization in cancer cells by nanoparticles: a systematic review. Adv Pharm Bull. 2021;11(2):212–223. doi:10.34172/apb.2021.025.
   PubMed Web of Science ®Google Scholar
• Talik Sisin NN, Abdul Razak K, Zainal Abidin S, Che Mat NF, Abdullah R, Ab Rashid R, Khairil Anuar MA, Rahman WN. synergetic influence of bismuth oxide nanoparticles, cisplatin and baicalein-rich fraction on reactive oxygen species generation and radiosensitization effects for clinical radiotherapy beams. Int J Nanomedicine. 2020. 15:7805–7823. doi:10.2147/IJN.S269214.
   PubMed Web of Science ®Google Scholar
• Miura M, Sasaki T. Role of glutathione in the intrinsic radioresistance of cell lines from a mouse squamous cell carcinoma. Radiat Res. 1991;126(2):229–236. doi:10.2307/3577823.
   PubMed Web of Science ®Google Scholar
• Patwardhan RS, Sharma D, Checker R, Thoh M, Sandur SK. Spatio-temporal changes in glutathione and thioredoxin redox couples during ionizing radiation-induced oxidative stress regulate tumor radioresistance. Free Radic Res. 2015;49(10):1218–1232. doi:10.3109/10715762.2015.1056180.
   PubMed Web of Science ®Google Scholar
• Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780–783. doi:10.1038/nature07733.
   PubMed Web of Science ®Google Scholar
• Sriramulu S, Ramachandran M, Subramanian S, Kannan R, Gopinath M, Sollano J, Bissi L, Banerjee A, Marotta F, Pathak S, et al. A review on role of ATM gene in hereditary transfer of colorectal cancer. Acta Biomed. 2019;89(4):463–469. doi:10.23750/abm.v89i4.6095.
   PubMedGoogle Scholar
• Angel M, Zarba M, Sade JP. PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer? Ecancermedicalscience. 2021;15:ed118. doi:10.3332/ecancer.2021.ed118.
   PubMedGoogle Scholar
• Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E. PARP inhibitors in combination with radiotherapy: to do or not to do? Cancers Basel. 2021;13(21):5380. doi:10.3390/cancers13215380.
   PubMed Web of Science ®Google Scholar
• Knelson EH, Patel SA, Sands JM. PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses. Cancers Basel. 2021;13(4):727. doi:10.3390/cancers13040727.
   PubMed Web of Science ®Google Scholar
• Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer. 2020;30(4):409–423. doi:10.1136/ijgc-2020-001227.
   PubMed Web of Science ®Google Scholar
• Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, Habrand J-L, Saintigny Y, Joly F. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–69124. doi:10.18632/oncotarget.19079.
   PubMedGoogle Scholar
• Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004;58(2):410–419. doi:10.1016/j.ijrobp.2003.09.053.
   PubMed Web of Science ®Google Scholar
• Dungey FA, Löser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008;72(4):1188–1197. doi:10.1016/j.ijrobp.2008.07.031.
   PubMed Web of Science ®Google Scholar
• Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res. 2014;20(19):5085–5096. doi:10.1158/1078-0432.CCR-14-1038.
   PubMed Web of Science ®Google Scholar
• Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour WY. Inhibition of PARP1-dependent end-joining contributes to olaparib-mediated radiosensitization in tumor cells. Mol Oncol. 2014;8(8):1616–1625. doi:10.1016/j.molonc.2014.06.008.
   PubMed Web of Science ®Google Scholar
• Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13(10):3033–3042. doi:10.1158/1078-0432.CCR-06-2872.
   PubMed Web of Science ®Google Scholar
• Liu C, Gross N, Li Y, Li G, Wang Z, Zhong S, Li Y, Hu G. PARP inhibitor olaparib increases the sensitization to radiotherapy in FaDu cells. J Cell Mol Med. 2020;24(4):2444–2450. doi:10.1111/jcmm.14929.
   PubMed Web of Science ®Google Scholar
• Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation. Mol Cancer Ther. 2019;18(11):2063–2073. doi:10.1158/1535-7163.MCT-19-0520.
   PubMed Web of Science ®Google Scholar
• Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16(1):621. doi:10.1186/s12885-016-2656-8.
   PubMedGoogle Scholar
• Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O’Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10(10):1949–1958. doi:10.1158/1535-7163.MCT-11-0278.
   PubMed Web of Science ®Google Scholar
• Cannan WJ, Pederson DS. Mechanisms and consequences of double-strand DNA break formation in chromatin. J Cell Physiol. 2016;231(1):3–14. doi:10.1002/jcp.25048.
   PubMed Web of Science ®Google Scholar
• Kong Y, Xu C, Sun X, Sun H, Zhao X, He N, Ji K, Wang Q, Du L, Wang J, et al. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair. Cancer Biol Med. 2021;19(8):1150–1171. doi:10.20892/j.issn.2095-3941.2021.0178.
   PubMed Web of Science ®Google Scholar
• Soni A, Li F, Wang Y, Grabos M, Krieger LM, Chaudhary S, Hasan MSM, Ahmed M, Coleman CN, Teicher BA, et al. Inhibition of Parp1 by BMN673 effectively sensitizes cells to radiotherapy by upsetting the balance of repair pathways processing DNA double-strand breaks. Mol Cancer Ther. 2018;17(10):2206–2216. doi:10.1158/1535-7163.MCT-17-0836.
   PubMed Web of Science ®Google Scholar
• Yu Z, Guo J, Meng T, Ge L, Liu L, Wang H, Yang X. Bcl-xL DNAzymes promote radiosensitivity and chemosensitivity in colorectal cancer cells via enhancing apoptosis. BMC Pharmacol Toxicol. 2022;23(1):13. doi:10.1186/s40360-022-00553-x.
   PubMed Web of Science ®Google Scholar
• Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma V-M, et al. Nad(p)h: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–853. doi:10.1038/ng.155.
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang H, Corbet C, de Mey S, Law K, Gevaert T, Feron O, De Ridder M. Piperlongumine increases sensitivity of colorectal cancer cells to radiation: involvement of ROS production via dual inhibition of glutathione and thioredoxin systems. Cancer Lett. 2019. 450:42–52. doi:10.1016/j.canlet.2019.02.034.
   PubMed Web of Science ®Google Scholar
• Fasih A, Elbaz HA, Hüttemann M, Konski AA, Zielske SP. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res. 2014;182(1):50–59. doi:10.1667/RR13568.1.
   PubMed Web of Science ®Google Scholar
• de Mey S, Jiang H, Corbet C, de Mey S, Wang H, Dufait I, Law K, Bastien E, Verovski V, Gevaert T, et al. Antidiabetic biguanides radiosensitize hypoxic colorectal cancer cells through a decrease in oxygen consumption. Front Pharmacol. 2018;9:1073. doi:10.3389/fphar.2018.01073.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang L, Zhang J, Zhou M, Shen L, Deng W, Liang L, Hu R, Yang W, Yao Y, et al. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol. 2018;53(4):1667–1680. doi:10.3892/ijo.2018.4514.
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Mehta RK, Kurapati H, Thomas DG, Lawrence TS, Nyati MK. Enhancing the radiation response in KRAS mutant colorectal cancers using the c-met inhibitor crizotinib. Transl Oncol. 2019;12(2):209–216. doi:10.1016/j.tranon.2018.10.005.
   PubMed Web of Science ®Google Scholar
• Chen YH, Wei MF, Wang CW, Lee H-W, Pan S-L, Gao M, Kuo S-H, Cheng A-L, Teng C-M. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357(2):582–590. doi:10.1016/j.canlet.2014.12.015.
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Christiansen S, Rieckmann T, Horn M, Frenzel T, Brinker A, Schumacher U, Stein A, Petersen C, Burdak-Rothkamm S, et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. Cancer Lett. 2020;493:179–188. doi:10.1016/j.canlet.2020.08.038.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Lee NG, Kang AR, Song J-Y, Hwang S-G, Um H-D, Kim J, Park JK. Radiosensitizer effect of β-apopicropodophyllin against colorectal cancer via induction of reactive oxygen species and apoptosis. Int J Mol Sci. 2021;22(24):13514. doi:10.3390/ijms222413514.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Lee NG, Kang AR, Ahn I-H, Choi I-Y, Song J-Y, Hwang S-G, Um H-D, Choi J-R, Kim J, et al. JNC-1043, a novel podophyllotoxin derivative, exerts anticancer drug and radiosensitizer effects in colorectal cancer cells. Molecules. 2022;27(20):7008. doi:10.3390/molecules27207008.
   PubMed Web of Science ®Google Scholar
• Heshmatian B, Behrouzkia Z, Mohammadian M, Moradi Z, Mohammadi Z, Zohdi Aghdam R, Zohdi Aghdam R. Cytotoxic and radiosensitizing effects of folic acid-conjugated gold nanoparticles and doxorubicin on colorectal cancer cells. Adv Pharm Bull. 2022;12(4):772–779. doi:10.34172/apb.2022.079.
   PubMed Web of Science ®Google Scholar
• Shiratori H, Kawai K, Hata K, Tanaka T, Nishikawa T, Otani K, Sasaki K, Kaneko M, Murono K, Emoto S, et al. The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells. Oncol Rep. 2019;42(1):377–385. doi:10.3892/or.2019.7134.
   PubMed Web of Science ®Google Scholar
• Liang H, Tang Y, Zhang H, Zhang C. MiR-32-5p regulates radiosensitization, migration and invasion of colorectal cancer cells by targeting TOB1 gene. OTT. 2019. 12:9651–9661. doi:10.2147/OTT.S228995.
   Google Scholar
• Wan J, Zhu J, Li G, Zhang Z. Radiosensitization of human colorectal cancer cells by MLN4924: an inhibitor of NEDD8-activating enzyme. Technol Cancer Res Treat. 2016;15(4):527–534. doi:10.1177/1533034615588197.
   PubMed Web of Science ®Google Scholar
• Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, et al. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: a matched-pair analysis. Adv Radiat Oncol. 2017;2(3):455–464. doi:10.1016/j.adro.2017.04.001.
   PubMedGoogle Scholar
• Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB, Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-κB activity. Int J Radiat Oncol Biol Phys. 2009;75(2):534–542. doi:10.1016/j.ijrobp.2009.06.034.
   PubMed Web of Science ®Google Scholar
• Choy CA, Robison BH, Gagne TO, Erwin B, Firl E, Halden RU, Hamilton JA, Katija K, Lisin SE, Rolsky C, et al. The vertical distribution and biological transport of marine microplastics across the epipelagic and mesopelagic water column. Sci Rep. 2019;9(1):7843. doi:10.1038/s41598-019-44117-2.
   PubMedGoogle Scholar
• Mohammadian M, Emamgholizadeh Minaei S, Shiralizadeh Dezfuli A. Improve the cytotoxic effects of megavoltage radiation treatment by Fe3O4@Cus–PEG nanoparticles as a novel radiosensitizer in colorectal cancer cells. Cancer Nano. 2022;13(1):25. doi:10.1186/s12645-022-00131-0.
   Web of Science ®Google Scholar
• Huang WL, Wu SF, Xu ST, Ma Y-C, Wang R, Jin S, Zhou S. Allicin enhances the radiosensitivity of colorectal cancer cells via inhibition of NF-κB signaling pathway. J Food Sci. 2020;85(6):1924–1931. doi:10.1111/1750-3841.15156.
   PubMed Web of Science ®Google Scholar
• Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995;92(18):8493–8497. doi:10.1073/pnas.92.18.8493.
   PubMed Web of Science ®Google Scholar
• Carter R, Westhorpe A, Romero MJ, Habtemariam A, Gallevo CR, Bark Y, Menezes N, Sadler PJ, Sharma RA. Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes. Sci Rep. 2016;6(1):20596. doi:10.1038/srep20596.
   PubMedGoogle Scholar
• Chen C, Zhu T, Liu X, Zhu D, Zhang Y, Wu S, Han C, Zhang H, Luo J, Kong L, et al. Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling. Acta Pharm Sin B. 2022;12(1):246–261. doi:10.1016/j.apsb.2021.06.008.
   PubMed Web of Science ®Google Scholar
• Van de Gucht M, Dufait I, Kerkhove L, Corbet C, de Mey S, Jiang H, Law KL, Gevaert T, Feron O, De Ridder M. Inhibition of phosphoglycerate dehydrogenase radiosensitizes human colorectal cancer cells under hypoxic conditions. Cancers Basel. 2022;14(20):5060. doi:10.3390/cancers14205060.
   PubMed Web of Science ®Google Scholar
• Huerta S, Gao X, Livingston EH, Kapur P, Sun H, Anthony T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery. 2010;148(2):346–353. doi:10.1016/j.surg.2010.05.006.
   PubMed Web of Science ®Google Scholar
• He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 2014;32(4):577–586. doi:10.1007/s10637-014-0095-4.
   PubMed Web of Science ®Google Scholar
• Ferreiro-Neira I, Torres NE, Liesenfeld LF, Chan CHF, Penson T, Landesman Y, Senapedis W, Shacham S, Hong TS, Cusack JC, et al. XPO1 inhibition enhances radiation response in preclinical models of rectal cancer. Clin Cancer Res. 2016;22(7):1663–1673. doi:10.1158/1078-0432.CCR-15-0978.
   PubMed Web of Science ®Google Scholar
• Kefayat A, Ghahremani F, Safavi A, Hajiaghababa A, Moshtaghian J. C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression. Sci Rep. 2019;9(1):19161. doi:10.1038/s41598-019-55605-w.
   PubMedGoogle Scholar
• Ha Thi HT, Kim HY, Kim YM, Hong S. MicroRNA-130a modulates a radiosensitivity of rectal cancer by targeting SOX4. Neoplasia. 2019;21(9):882–892. doi:10.1016/j.neo.2019.07.005.
   PubMed Web of Science ®Google Scholar